Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Technological Advancements in Radiology and Chemotherapy
4.2.2 Increasing Incidence and Prevalence of Colorectal Cancer
4.3 Market Restraints
4.3.1 High Costs and the Side Effects Associated with Drugs
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Modality
5.1.1 Diagnostics Techniques
5.1.1.1 Stool Tests
5.1.1.2 Immunohistochemistry
5.1.1.3 Colonoscopy
5.1.1.4 Flexible Sigmoidoscopy
5.1.1.5 Other Diagnostics Techniques
5.1.2 Therapeutics
5.1.2.1 Chemotherapy
5.1.2.2 Immunotherapy
5.1.2.3 Others
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle-East
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle-East
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Amgen Inc.
6.1.3 Clinical Genomics
6.1.4 EDP Biotech
6.1.5 Epigenomics AG
6.1.6 F. Hoffmann-La Roche AG
6.1.7 Novigenix SA
6.1.8 Quest Diagnostics
6.1.9 Sanofi SA
6.1.10 Siemens Healthineers
6.1.11 VolitionRX


7 MARKET OPPORTUNITIES AND FUTURE TRENDS